Canada-based Aurora Cannabis Inc (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced yesterday that it has named Nelson Peltz as its new strategic advisor.
Peltz is the chief executive officer and a founding partner of Trian Fund Management LP. He also currently serves as the non-executive chairman of The Wendy's Company and as a director of The Procter & Gamble Company, Sysco Corporation, and The Madison Square Garden Company. He was earlier a director of H J Heinz Company, Legg Mason Inc, Ingersoll-Rand plc, and Mondelez International Inc, among other companies. He formerly served as chairman and chief executive officer of Triarc Companies Inc which during his tenure owned Arby's Restaurant Group Inc and the Snapple Beverage Group, as well as other consumer and industrial businesses. He was also chairman and chief executive officer of Triangle Industries Inc. He started his business career by joining his family's food distribution business. His advisory services to Aurora will be provided through 280 Park ACI Holdings LLC.
Terry Booth, CEO, said, 'Nelson is a globally recognized business visionary with a strong track record of constructive engagement to generate accelerated, profitable growth and shareholder value across many industry verticals that are of great interest to us. Like us, Nelson also takes a long-term view of value creation to benefit all stakeholders. We look forward to working with Nelson to further extend our global cannabis industry leadership by aligning Aurora with each of the major market segments cannabis is set to impact.'
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer